MX357936B - Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente. - Google Patents

Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente.

Info

Publication number
MX357936B
MX357936B MX2015007213A MX2015007213A MX357936B MX 357936 B MX357936 B MX 357936B MX 2015007213 A MX2015007213 A MX 2015007213A MX 2015007213 A MX2015007213 A MX 2015007213A MX 357936 B MX357936 B MX 357936B
Authority
MX
Mexico
Prior art keywords
antibodies
solution formulations
engineered anti
formulations
high concentration
Prior art date
Application number
MX2015007213A
Other languages
English (en)
Other versions
MX2015007213A (es
Inventor
Ramesh S Kashi
Aniket Badkar
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357936(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015007213A publication Critical patent/MX2015007213A/es
Publication of MX357936B publication Critical patent/MX357936B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones de la solución de concentración alta de anticuerpo hum13B8-b de anti-interleuquina 23 p19 humana (IL-23p19), y su uso en el tratamiento de varios trastornos.
MX2015007213A 2012-12-13 2013-12-09 Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente. MX357936B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (2)

Publication Number Publication Date
MX2015007213A MX2015007213A (es) 2016-08-03
MX357936B true MX357936B (es) 2018-07-31

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007213A MX357936B (es) 2012-12-13 2013-12-09 Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente.

Country Status (31)

Country Link
US (3) US20150329632A1 (es)
EP (1) EP2931313B1 (es)
JP (1) JP6266012B2 (es)
KR (1) KR102004585B1 (es)
CN (1) CN104870016B (es)
AU (1) AU2013359767B2 (es)
BR (1) BR112015013540B1 (es)
CA (1) CA2894869C (es)
CL (1) CL2015001608A1 (es)
CY (1) CY1121895T1 (es)
DK (1) DK2931313T3 (es)
EA (1) EA034616B1 (es)
ES (1) ES2732861T3 (es)
HK (1) HK1215194A1 (es)
HR (1) HRP20191137T1 (es)
HU (1) HUE045668T2 (es)
IL (3) IL307581A (es)
LT (1) LT2931313T (es)
MX (1) MX357936B (es)
MY (1) MY187921A (es)
NZ (1) NZ708443A (es)
PE (1) PE20151524A1 (es)
PH (1) PH12015501296B1 (es)
PL (1) PL2931313T3 (es)
PT (1) PT2931313T (es)
RS (1) RS59057B1 (es)
SI (1) SI2931313T1 (es)
TR (1) TR201909584T4 (es)
UA (1) UA117466C2 (es)
WO (1) WO2014093203A1 (es)
ZA (1) ZA201504408B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3603669B1 (en) * 2017-03-31 2024-06-19 Meiji Seika Pharma Co., Ltd. Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method
IL310216A (en) * 2018-03-05 2024-03-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
EA202191403A1 (ru) 2018-11-21 2021-08-09 Ридженерон Фармасьютикалз, Инк. Композиция с высокой концентрацией белка
KR20210096559A (ko) 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항IL-23p19 항체 및 이의 용도
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
JP7530376B2 (ja) * 2019-02-20 2024-08-07 アムジエン・インコーポレーテツド タンパク質の安定性を決定する方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
AU2020409124A1 (en) 2019-12-20 2022-06-30 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
TWI802882B (zh) * 2020-05-13 2023-05-21 大陸商信達生物制藥(蘇州)有限公司 包含抗IL-23p19抗體的製劑、其製備方法和用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159299B1 (en) 1999-03-11 2009-01-14 Schering Corporation Mammalian cytokines; related reagents and methods
ES2300276T5 (es) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
PL1601694T3 (pl) 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
JP4903061B2 (ja) 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20090181027A1 (en) 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
PT2234600E (pt) 2007-12-21 2014-09-25 Hoffmann La Roche Formulação de anticorpos
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
RU2518278C2 (ru) * 2008-09-19 2014-06-10 Пфайзер Инк. Стабильный жидкий препарат антитела
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
TR201810298T4 (tr) * 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
EP3912639A1 (en) * 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies

Also Published As

Publication number Publication date
PE20151524A1 (es) 2015-11-06
IL278295A (es) 2020-12-31
BR112015013540B1 (pt) 2021-04-27
PL2931313T3 (pl) 2019-10-31
PH12015501296A1 (en) 2015-08-24
CA2894869A1 (en) 2014-06-19
US20150329632A1 (en) 2015-11-19
KR20150092763A (ko) 2015-08-13
CN104870016A (zh) 2015-08-26
BR112015013540A2 (pt) 2017-11-14
AU2013359767B2 (en) 2018-04-05
PT2931313T (pt) 2019-07-10
PH12015501296B1 (en) 2015-08-24
MY187921A (en) 2021-10-28
WO2014093203A1 (en) 2014-06-19
US20240239884A1 (en) 2024-07-18
CL2015001608A1 (es) 2015-10-30
HK1215194A1 (zh) 2016-08-19
IL239150A0 (en) 2015-07-30
ES2732861T3 (es) 2019-11-26
DK2931313T3 (da) 2019-07-15
EA034616B1 (ru) 2020-02-27
BR112015013540A8 (pt) 2018-04-17
AU2013359767A1 (en) 2015-07-23
JP2016505572A (ja) 2016-02-25
KR102004585B1 (ko) 2019-07-26
NZ708443A (en) 2018-05-25
EA201591133A1 (ru) 2015-10-30
HRP20191137T1 (hr) 2019-09-20
SI2931313T1 (sl) 2019-09-30
US20210188964A1 (en) 2021-06-24
CY1121895T1 (el) 2020-10-14
UA117466C2 (uk) 2018-08-10
RS59057B1 (sr) 2019-08-30
IL307581A (en) 2023-12-01
IL278295B1 (en) 2023-11-01
CN104870016B (zh) 2018-05-08
LT2931313T (lt) 2019-09-25
TR201909584T4 (tr) 2019-07-22
ZA201504408B (en) 2017-09-27
EP2931313A4 (en) 2016-08-03
IL239150B (en) 2020-11-30
CA2894869C (en) 2021-06-15
MX2015007213A (es) 2016-08-03
HUE045668T2 (hu) 2020-01-28
EP2931313B1 (en) 2019-05-08
IL278295B2 (en) 2024-03-01
JP6266012B2 (ja) 2018-01-24
EP2931313A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
PH12015501296B1 (en) Solution formulations of engineered anti-il-23p19 antibodies
ZA202206078B (en) Anti-cd3 antibodies and methods of use
MX2020002289A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
TN2015000050A1 (en) Methods of treating a tauopathy
MX347020B (es) Anticuerpo contra el csf-1r.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
NZ702195A (en) Anti-ly6e antibodies and immunoconjugates and methods of use
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
MX2013011012A (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
EA201592203A1 (ru) Способы лечения таупатии
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
MY192384A (en) Anti-cd3 antibodies and methods of use

Legal Events

Date Code Title Description
FG Grant or registration